Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Junichiro Yuda(National Cancer Center Hospital East), Andrew J. Souers(AbbVie (United States))
Cited by 62
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
|ACS Medicinal Chemistry Letters|2014|331
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
|Journal of Medicinal Chemistry|2015|152